Dietary Habits, Metabolome, Immune Profile and Microbiota in Patients With Bone Sarcoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

810 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-03-10

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Osteosarcoma and Ewing sarcoma treatment has not changed in the last 30 years.

For other types of cancer the epidemiologic and prognostic correlations between dietary behavior, lifestyle and metabolic alterations (i.e.obesity, insulin-resistance) are well known (breast cancer, prostate cancer, colon cancer). However, no epidemiological or prognostic data are available about the metabolic profile and lifestyle behaviors in patients with osteosarcoma and Ewing'sarcoma and only few preclinical studies are available. An in vitro study showed a higher glucose and glutamine consumption from metastatic osteosarcoma cells compared to primary tumor osteosarcoma cells. The effect of the intestinal microbiota into the metabolism of nutrients, drugs, inflammation, epigenetic and immune response was found not only correlated to gastrointestinal tumors but also to other tumors outside gastrointestinal system as well The aim of this study is to investigate if there are differential dietary habits, metabolome, microbiota or immune profile in patients with bone sarcoma compared to a control population in a 1:2 multicenter study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Development of Innovative Preclinical Ex Vivo Models for the Study of Sarcomas and Metastases From Solid Tumors

NCT07112989

Bone and Soft Tissue Tumors Bone Metastases From Solid Tumors Lung Metastases

RECRUITING

Correlation of Metabolic Imaging With Immune Markers in NSCLC Candidate to Immunotherapy.

NCT03563482

Carcinoma, Non-Small-Cell Lung Positron-Emission Tomography Immunotherapy

UNKNOWN NA

Machine Learning Applied to EHRs Data of Patients With Sarcoma

NCT07215728

Sarcoma Osteosarcoma Ewing Sarcoma

COMPLETED

Nutritional Status in Locally Advanced or Metastatic Solid Cancer Patients in Spain: the NutriOncoSearch (NOS) Study

NCT04168814

Malnutrition Oncologic Complications Oncology +1 more

COMPLETED

Evaluation of Tumor Resection and Reconstruction With Prosthetic Implants

NCT07337018

Bone Tumor

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

MATERIALS \& METHODS A population of 270 patients of \>12 yrs old (pediatric and adults) with new diagnosis of osteosarcoma and Ewing sarcoma will be included. A detailed dietary intake assessment will be done with EPIC-COS food frequency questionnaire (FFQ) and anthropometric measures (Weight, Height, body fat/lean mass composition) will be taken at diagnosis before treatment and compared to 540 controls matched by age, sex, and italian geographic area.

In addition, inside this main study a pilot study of 55 patients and 110 controls of same age, sex, geographic area will be performed for analysis of metabolome, microbiota, and immune profile.

At diagnosis, before any treatment , a blood sample will be obtained for metabolomics analyses (untargeted approach with over 100.000 of metabolites, (Mass Spectrometry method) and to evaluate lymphocyte subpopulations (CD3, CD4, CD8, NK) in blood. Microbiota will be analyzed in donated stool samples using the S16 method. All data will be analyzed for inter-correlations among the different parameters and to investigate putative associations with EPIC-COS Food Frequency questionnaires and anthropometric data .

STATISTICAL ANALYSIS Conditional logistic regression analyses will be used to calculate odds ratio (OR) and 95% confidence interval (CI) to investigate associations between dietary habits and bone sarcoma risk in the case control study. An odds ratio of 1.6 with a potency of 85% was considered in the sample size calculations, leading to a target sample size of 270 cases with 540 matched healthy controls.

For the pilot cohort samples of 55 cases and 110 controls will be analyzed for metabolome, microbiota and immune profile. According to the results of this pilot study further cases among the population of FFQ study will undertake further analysis of metabolome and/or microbiota and/or lymphocyte subpopulation to confirm the results of pilot study.

OBJECTIVES OF THE STUDY

1. Compare the diet habits and anthropometric measures in bone sarcoma patients at diagnosis with matched controls
2. Pilot study: in the first 55 pts and their matched 110 healthy voluntary controls will be explored:

1. the occurrence of altered or more recurrent metabolites in patients' blood compared to controls
2. different microbiota diversity and composition between patients and case controls
3. different lymphocytes subpopulations composition.

Bioinformatics analysis will be performed to investigate these objectives

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteosarcoma Ewing Sarcoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

GROUP 1 - 215 Patients and 430 Control cases (1:2)

Patients of \>= 12 years old (pediatric and adults) with new diagnosis of osteosarcoma and Ewing sarcoma will be included

* Localized and metastatic
* Male and female

Control cases matched by age, sex and italian geographic area

EPIC-COS Food Frequency Questionnaire diet Evaluation

Intervention Type OTHER

Anthropometric measurements (Body mass Index, Lean and fat body composition evaluation) and diet habits evaluation with EPIC-COS-FFQ

GROUP 2 - Pilot Phase :55 Patients and 110 Control cases (1:2)

* Patients of \>= 12 years old (pediatric and adults) with new diagnosis of osteosarcoma and Ewing sarcoma will be included Localized and metastatic Male and female
* Control cases matched by age, sex, and geographic area

EPIC-COS Food Frequency Questionnaire diet Evaluation

Intervention Type OTHER

Anthropometric measurements (Body mass Index, Lean and fat body composition evaluation) and diet habits evaluation with EPIC-COS-FFQ

Metabolome, Microbiota, Lymphocytes subpopulations

Intervention Type OTHER

At diagnosis before any treatment for bone sarcoma will be obtained :

1. a blood sample for metabolomics analyses
2. a stool sample for microbiota analysis
3. Lymphocyte subpopulations (CD3, CD4, CD8, NK) will be analyzed in blood samples

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

EPIC-COS Food Frequency Questionnaire diet Evaluation

Anthropometric measurements (Body mass Index, Lean and fat body composition evaluation) and diet habits evaluation with EPIC-COS-FFQ

Intervention Type OTHER

Metabolome, Microbiota, Lymphocytes subpopulations

At diagnosis before any treatment for bone sarcoma will be obtained :

1. a blood sample for metabolomics analyses
2. a stool sample for microbiota analysis
3. Lymphocyte subpopulations (CD3, CD4, CD8, NK) will be analyzed in blood samples

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

EPIC-FFQ diet Evaluation

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Osteosarcoma and Ewing sarcoma first diagnosis
* No previous chemotherapy treatment
* ≥ 12 years old
* Able to understand the questionnaire
* No malignant tumor diagnosis for the last 5 years
* Control case should have a range of +/- 2 years old for patients \>= 21 years old. For patients between 12 and 21 years old the difference should be +/- 1 years.

Exclusion Criteria

* Other tumor type
* Not able to understand the questionnaire
* Patient diagnosed for malignant tumor during the last 5 years

Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Alessandra Longhi,MD

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alessandra Longhi, MD

Role: PRINCIPAL_INVESTIGATOR

Istituto Ortopedico Rizzoli - Bologna

Locations

Explore where the study is taking place and check the recruitment status at each participating site.